



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/598,275

03/28/2007

Ryozo Nagai

P30563

2170

7055 7590 02/02/2011
GREENBLUM & BERNSTEIN, P.L.C.
1950 ROLAND CLARKE PLACE
RESTON, VA 20191

EXAMINER

PURDY, KYLE A

ART UNIT

PAPER NUMBER

1611

NOTIFICATION DATE

DELIVERY MODE

02/02/2011

ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

gbpatent@gbpatent.com
pto@gbpatent.com

Art Unit: 1611

Applicants arguments filed 1/18/2011 regarding the rejection of claims 24, 28, 29 and 32-40 made by the Examiner under 35 USC 103(a) over Marx in view of Shidoji, evidenced by English equivalent US 2005/0250671 have been fully considered but they are not found persuasive and are **MAINTAINED**.

In regards to the 103(a) rejection, Applicant asserts the following:

A) the claims now recite (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid.

In response to A, Applicants is argument is not persuasive because this very same compound is taught by Shidoji and its use in a method for the treatment of arteriosclerosis would have been obvious. A